9th Nov 2020 09:05
(Alliance News) - CSL Ltd on Sunday confirmed it will start manufacturing the AZD1222 Covid-19 vaccine candidate from the University of Oxford and AstraZeneca PLC at its advanced manufacturing facility in Broadmeadows, Australia.
The biotechnology company said it has separate contracts with AstraZeneca and the Australian government to manufacture 30 million doses of the AZD1222 vaccine candidate, with first doses planned for release in the first half of 2021, pending the outcome of clinical trials and regulatory approval.
"The AZD1222 vaccine has been granted a provisional determination by the Therapeutic Goods Administration in Australia," said CSL Chief Scientific Officer Andrew Nash.
"There's still a long way to go and our first priority resolutely remains the safety and efficacy of the vaccines we produce. We are undertaking these manufacturing activities at-risk and in parallel with the clinical trials and approvals processes in recognition of the significant urgency of the Covid-19 pandemic," added Nash.
CSL shares closed 1.0% higher in Sydney on Monday at AUD304.92 each.
By Evelina Grecenko; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca